Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Published:2018-07 Issue:7 Volume:19 Page:975-986
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Clarke Noel,Wiechno Pawel,Alekseev Boris,Sala Nuria,Jones Robert,Kocak Ivo,Chiuri Vincenzo Emanuele,Jassem Jacek,Fléchon Aude,Redfern Charles,Goessl Carsten,Burgents Joseph,Kozarski Robert,Hodgson Darren,Learoyd Maria,Saad Fred

Publisher

Elsevier BV

Subject

Oncology

Reference24 articles.

1. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARC CancerBase No. 11;Ferlay,2014

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. DNA-repair defects and olaparib in metastatic prostate cancer;Mateo;N Engl J Med,2015

4. Trapping of PARP1 and PARP2 by clinical PARP inhibitors;Murai;Cancer Res,2012

5. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy;Farmer;Nature,2005

Cited by 315 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer de prostate métastatique résistant à la castration et inhibiteurs de PARP : de la génomique tumorale aux nouvelles associations thérapeutiques;Bulletin du Cancer;2024-09

2. Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer;International Journal of Molecular Sciences;2024-08-26

3. Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No;European Urology Focus;2024-08

4. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer;Drugs;2024-07-26

5. Circulating tumor extracellular vesicles to monitor metastatic prostate cancer genomics and transcriptomic evolution;Cancer Cell;2024-07